Trial record 7 of 752 for:    Open Studies | "Hemorrhage"

Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring

This study is currently recruiting participants.
Verified November 2013 by Medical University of Vienna
Sponsor:
Information provided by (Responsible Party):
Nadja Haiden,MD, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01976013
First received: October 29, 2013
Last updated: November 4, 2013
Last verified: November 2013
  Purpose

Up to now, only data about early and single coagulation screening exist in extreme low birth weight infants (ELBW) infants. In neonatal practice, coagulation abnormality in preterm babies is primarily investigated by measuring prothrombin time (PT). In fact, FVII activity, which is an important determinant of PT, is strongly associated with bleeding risk. Thus, a method to measure PT with small volume samples (10μL) provides the possibility for serial monitoring even in ELBW infants (CoaguChek®XS, Roche Diagnostics, Vienna, Austria)). Substitution of fesh frozen plasma seemed beneficial in ELBW infants and first trials with rFVII revealed promising results in this patient population. Thus, coagulation monitoring might lead to early and adequate therapy and therefore to a better outcome. The investigators hypothesize that ELBW infants (<1000g birth weight) with primary severe prolongation of prothrombin time or development of severe prothrombin prolongation during sequential monitoring may have more frequent and more severe bleeding incidents (Intraventricular haemorrhage and pulmonary haemorrhage). The investigators aim to explore whether monitoring of PT can predict bleeding events in ELBW children.


Condition Intervention
Intraventricular Haemorrhage
Pulmonary Haemorrhage
Device: Coaguchek

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Prediction of Major Bleeding in Extremely Low Birth Weight Infants (<1000g) by Sequential Coagulation Monitoring

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • major bleeding [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    pulmonary bleeding, intraventricular hemorrhage


Secondary Outcome Measures:
  • mortality [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 126
Study Start Date: October 2013
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Coaguchek
infants will receive sequential coagulation checks
Device: Coaguchek
The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.

  Eligibility

Ages Eligible for Study:   up to 7 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Preterm infants with a birth weight <1000g
  • signed informed consent

Exclusion Criteria:

  • Congenital heart disease
  • major congenital birth defects
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01976013

Contacts
Contact: Nadja Haiden, MD +431404003232 nadja.haiden@meduniwien.ac.at
Contact: Margarita Thanhaeuser, MD +431404003232 margarita.thanhaeuser@meduniwien.ac.at

Locations
Austria
Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Nadja Haiden, MD    +431404003232    nadja.haiden@meduniwien.ac.at   
Principal Investigator: Nadja Haiden, MD         
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Nadja Haiden, MD Medical University Vienna
  More Information

No publications provided

Responsible Party: Nadja Haiden,MD, Assoc.Prof.MD, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01976013     History of Changes
Other Study ID Numbers: MUV-Coagu
Study First Received: October 29, 2013
Last Updated: November 4, 2013
Health Authority: Austria: Ethikkommission

Keywords provided by Medical University of Vienna:
PT
INR
intraventricular haemorrhage
pulmonary haemorrhage
ELBW infants

Additional relevant MeSH terms:
Hemorrhage
Cerebral Hemorrhage
Intracranial Hemorrhages
Hemoptysis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 17, 2014